Author

Dharma R. Thapa

Dana-Farber Cancer Institute

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Approach:experimental assay· 1 Approach:machine learning (classical)· 1

Frequent Co-Authors

Jiao LiiD· 2 shared Prathyusha KondaiD· 2 shared Riva Deodhar· 2 shared Srinivas Raghavan ViswanathaniD· 2 shared Yantong Cui· 2 shared Adam P. SkepneriD· 1 shared Alison LeediD· 1 shared Ananthan SadagopaniD· 1 shared

Activity by Year

2024-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 39 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Jiao LiORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Phenotypic screening converges on CDK9 inhibition as a therapeutic strategy in translocation renal cell carcinoma

Dharma R. Thapa, Riva Deodhar, Adam P. Skepner, Prathyusha Konda, Meng Zhou, Joseph P. Bluck, C. Pichlo, Yantong Cui, Paige Stocker, Prateek Khanna, Jiao Li, Jonathan M. Tsai, Alison Leed, Sandy Gould, Maria Alimova, , Srinivas Raghavan Viswanathan

The paper identifies CDK9 inhibition as a therapeutic strategy for translocation renal cell carcinoma through phenotypic screening and mechanistic analysis.

bioRxiv · Aug 25, 2025 · PreprintCancer Biology

Cancer target discovery enabled by transcriptome-based virtual CRISPR screening

Ananthan Sadagopan, Bingchen Li, Jiao Li, Yantong Cui, Riva Deodhar, Di Yang, Yifan Wu, Prathyusha Konda, Christy Biji, Dharma R. Thapa, Meha Thakur, Cary N. Weiss, Toni K. Choueiri, Jaimie H. Cheah, John G. Doench, , Srinivas Raghavan Viswanathan

This study uses machine learning to infer gene dependencies from tumor transcriptomes, identifying cancer vulnerabilities in rare cancers without experimental screening.

bioRxiv · Oct 24, 2024 · PreprintCancer Biology